abstract |
The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK + mediated condition such as EML4-ALK + non-small cell lung cancer, and optionally resistant to crizotinib; wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined above. |